about
Immunology of hepatocellular carcinomaSerum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.Clinical significance of sIL-2R levels in B-cell lymphomas.Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25).Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemiaSoluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.Placenta-specific expression of the interleukin-2 (IL-2) receptor β subunit from an endogenous retroviral promoter.Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomasSerum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review.Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vitroPrimary CNS lymphoma treated with radiotherapy in Japan: a survey of patients treated in 2005-2009 and a comparison with those treated in 1985-2004.Human papillomavirus typing and soluble interleukin-2 receptor levels in female sex workers with a negative cervical smear result.Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.Effect of allogeneic blood transfusion on levels of IL-6 and sIL-R2 in peripheral blood of children with acute lymphocytic leukemia.
P2860
Q26795411-F59A4354-5C89-4D29-9015-FCD571E70FE3Q34894332-A6983179-9E35-4040-A55E-BC1C9D7738F1Q35034487-6FE06AFF-A8DE-4225-8828-3C1C9FE77960Q35043560-0DD35EEA-02AF-4E8F-985F-D1D2C62432C6Q35179207-743D6A70-EE2D-49A6-B121-B0861565C6B4Q35210494-65A4A5D5-C9BA-425A-82BC-557418AF1985Q35212373-8F02C8CF-13CE-4CE8-A514-7C49A6F4BB14Q35371896-C46B3E28-CBFC-421B-91F1-7613A3D76555Q36089304-80A236EA-62CF-4441-9C4F-4DC2ECCC6C6FQ36201411-49BA19B0-6CE3-470A-8D28-52A6BD2C3462Q36956380-E5BC99F4-4A27-4328-9E09-0000FD584189Q37143220-C525553B-62CC-4260-9ED2-2410A0C40049Q46459281-00968516-A116-464B-ADE7-F25470A0B002Q47740892-2EECC137-2DB3-4C52-8056-4E42748B63D3Q53100526-72419C30-D7E9-419C-9058-563985DE39CDQ55512837-B7B8CF25-1749-44A6-A4F8-96385ECF740D
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Soluble interleukin-2 receptor in cancer.
@ast
Soluble interleukin-2 receptor in cancer.
@en
Soluble interleukin-2 receptor in cancer.
@nl
type
label
Soluble interleukin-2 receptor in cancer.
@ast
Soluble interleukin-2 receptor in cancer.
@en
Soluble interleukin-2 receptor in cancer.
@nl
prefLabel
Soluble interleukin-2 receptor in cancer.
@ast
Soluble interleukin-2 receptor in cancer.
@en
Soluble interleukin-2 receptor in cancer.
@nl
P356
P1476
Soluble interleukin-2 receptor in cancer.
@en
P2093
Saburo Murakami
P304
P356
10.2741/1461
P577
2004-09-01T00:00:00Z